Metraipolis › archive › dc_830d3482d1e2
[Appropriate Duration of First-line Immunotherapy for Advanced NSCLC and Predictive Factors] — Europe PMC PMID:41916913
- Source
- Europe PMC (chi)
- Original
- https://europepmc.org/article/MED/41916913
- DOI
- 10.3779/j.issn.1009-3419.2026.106.01
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T05:01:04.572Z
- SHA-256 of the archived text
2439bfa46f11fb8441b961d2dea4a36ffe2141e91d52a0c2016313084ad95d6f- Stable URL of this page
https://metraipolis.com/documento/dc_830d3482d1e2
How to cite
[Appropriate Duration of First-line Immunotherapy for Advanced NSCLC and Predictive Factors] — Europe PMC PMID:41916913 — Europe PMC (chi), https://europepmc.org/article/MED/41916913 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_830d3482d1e2 (Metraipolis archive dc_830d3482d1e2, sha256 2439bfa46f11fb8441b961d2dea4a36ffe2141e91d52a0c2016313084ad95d6f)
BibTeX
@misc{dc830d3482d1e2,
title = {[Appropriate Duration of First-line Immunotherapy for Advanced NSCLC and Predictive Factors] — Europe PMC PMID:41916913},
howpublished = {Europe PMC (chi)},
url = {https://europepmc.org/article/MED/41916913},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_830d3482d1e2; sha256 2439bfa46f11fb8441b961d2dea4a36ffe2141e91d52a0c2016313084ad95d6f},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41916913. Agents can read the archived copy with the MCP tool read_document.